[go: up one dir, main page]

AR062390A1 - Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas - Google Patents

Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas

Info

Publication number
AR062390A1
AR062390A1 ARP070103634A ARP070103634A AR062390A1 AR 062390 A1 AR062390 A1 AR 062390A1 AR P070103634 A ARP070103634 A AR P070103634A AR P070103634 A ARP070103634 A AR P070103634A AR 062390 A1 AR062390 A1 AR 062390A1
Authority
AR
Argentina
Prior art keywords
hemangioblastomas
treatment
hemangioms
dihydroxibengen
derivatives
Prior art date
Application number
ARP070103634A
Other languages
English (en)
Inventor
Sanchez Pedro Cuevas
Gallego Guillermo Gimenez
De Tejada Gorman Inigo Saenz
Frutos Javier Angulo
Lopez Serafin Valverde
Garrido Antonio Romero
Puerto Rosa Maria Lozano
Original Assignee
Action Medicines Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200602217A external-priority patent/ES2315117B1/es
Application filed by Action Medicines Sl filed Critical Action Medicines Sl
Publication of AR062390A1 publication Critical patent/AR062390A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente se refiere al uso de un compuesto de formula (1) o una sal o solvato, isomero o profármaco farmacéuticamente aceptables del mismo en la fabricacion de un medicamento para el tratamiento y/o profilaxis de una enfermedad seleccionada de hemangiomas y hemangioblastomas.
ARP070103634A 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas AR062390A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200602217A ES2315117B1 (es) 2006-08-16 2006-08-16 Uso de derivados 2,5-dihidroxibencenicos en la preparacion de medicamentos utiles en el tratamiento de asma.
ES200701855 2007-07-02

Publications (1)

Publication Number Publication Date
AR062390A1 true AR062390A1 (es) 2008-11-05

Family

ID=38515369

Family Applications (5)

Application Number Title Priority Date Filing Date
ARP070103637A AR062393A1 (es) 2006-08-16 2007-08-16 Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
ARP070103639A AR062395A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
ARP070103634A AR062390A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
ARP070103640A AR062396A1 (es) 2006-08-16 2007-08-16 Uso de derivados de 2,5-dihidroxibenceno para el tratamiento de enfermedades angiogenicas
ARP070103643A AR062399A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP070103637A AR062393A1 (es) 2006-08-16 2007-08-16 Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
ARP070103639A AR062395A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP070103640A AR062396A1 (es) 2006-08-16 2007-08-16 Uso de derivados de 2,5-dihidroxibenceno para el tratamiento de enfermedades angiogenicas
ARP070103643A AR062399A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido

Country Status (8)

Country Link
US (2) US20080114063A1 (es)
EP (3) EP2056805B1 (es)
AR (5) AR062393A1 (es)
AT (2) ATE509621T1 (es)
CL (5) CL2007002386A1 (es)
ES (1) ES2495965T3 (es)
PT (3) PT2056805E (es)
WO (5) WO2008020033A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149618A1 (en) * 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US20080125485A1 (en) 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
ES2238924B1 (es) * 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
PT2056813E (pt) * 2006-08-16 2013-08-23 Amderma Pharmaceuticals Llc Compostos de 2,5-di-hidroxibenzeno para o tratamento da rosácea
WO2009103069A1 (en) 2008-02-15 2009-08-20 Osborne David W Skin penetration enhancing systems for polar drugs
FR2951085B1 (fr) * 2009-10-09 2012-05-18 Inst Substances Vegetales Utilisation de composes phenoliques pour la deglycation des proteines
ES2385160B1 (es) * 2010-12-23 2013-05-24 Italfármaco, S.A. Compuestos con actividad inhibitoria de factores de crecimiento de fibroblastos.
EP2777699B1 (en) * 2012-02-02 2017-03-29 Invesfovea S.L. Diethylamine-2,5-dihydroxybenzenesulfonate for the treatment of age-related macular degeneration
PL404138A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
EP3167881B1 (en) * 2015-10-19 2019-08-28 Dobecure, S.L. Locally administered ethamsylate as a medicament

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115648A (en) * 1974-09-13 1978-09-19 Laboratorios Del Dr. Esteve, S.A. 2,5-Dihydroxy benzene sulfonic acid mono esters
US4513007A (en) * 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
US4617311A (en) * 1985-05-17 1986-10-14 Eli Lilly And Company Antiasthmatic method
CH679372A5 (es) * 1989-04-07 1992-02-14 Vet Gerhard Stuker Dr Med
CH682716A5 (de) * 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5374772A (en) * 1992-12-08 1994-12-20 Hoffmann-Laroche Inc. Substituted benzoic acids, inhibitors of phospholipases A2
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6114383A (en) * 1997-02-14 2000-09-05 Kissei Pharmaceutical Co., Ltd. Drugs inhibiting progress of pterygium and postoperative recurrence of the same
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
ATE272391T1 (de) * 1998-12-23 2004-08-15 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
JP2003501488A (ja) * 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US20020037897A1 (en) * 2000-08-07 2002-03-28 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
JP2002193800A (ja) * 2000-12-22 2002-07-10 Taisho Pharmaceut Co Ltd Ｖｅｇｆ受容体拮抗剤
CA2439463A1 (en) * 2001-02-28 2002-09-06 Anders Hallberg Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
WO2003024452A1 (de) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation
US7163958B2 (en) * 2002-07-03 2007-01-16 Nitromed Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
RU2002120366A (ru) * 2002-08-01 2005-02-27 БиоДием Лимитед (AU) Новые производные имидазолия и фармацевтические композиции на их основе
US7553867B2 (en) * 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
WO2004067009A1 (en) * 2003-01-29 2004-08-12 Dal-Hoon Son Pharmaceutical composition comprising an extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
WO2005013949A2 (en) * 2003-08-07 2005-02-17 Allergan, Inc. Method for treating cachexia with retinoid ligands
GB0321228D0 (en) * 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
WO2005051356A1 (en) * 2003-10-31 2005-06-09 Elan Pharma International Ltd. Novel nimesulide compositions
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives
EP1836160A1 (en) * 2004-12-24 2007-09-26 CTG Pharma S.r.l. Compounds for treating metabolic syndrome
EP1676573A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
EP1749820A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salts of substituted pyrazoline compounds, their preparation and use as medicaments
AU2006278596A1 (en) * 2005-08-04 2007-02-15 Novartis Ag Salts of vildagliptin
CN100506804C (zh) * 2006-01-26 2009-07-01 于学敏 羟苯磺酸烷基吡嗪药物及其制备方法和应用
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
WO2007113855A1 (en) * 2006-03-30 2007-10-11 Council Of Scientific & Industrial Research A bioactive fraction from zingiber officinale and a process for the preparation thereof

Also Published As

Publication number Publication date
CL2007002388A1 (es) 2008-01-18
US20110152222A1 (en) 2011-06-23
PT2054045E (pt) 2011-08-31
EP2054045B1 (en) 2011-05-18
US20080114063A1 (en) 2008-05-15
WO2008020031A1 (en) 2008-02-21
WO2008020032A1 (en) 2008-02-21
WO2008020042A1 (en) 2008-02-21
CL2007002392A1 (es) 2008-01-18
AR062395A1 (es) 2008-11-05
PT2056804E (pt) 2014-07-11
EP2056804B1 (en) 2013-05-22
WO2008020032A8 (en) 2008-04-17
EP2056805A1 (en) 2009-05-13
EP2054045A1 (en) 2009-05-06
EP2056805B1 (en) 2011-05-25
WO2008020033A1 (en) 2008-02-21
EP2056804A1 (en) 2009-05-13
CL2007002386A1 (es) 2008-01-18
AR062396A1 (es) 2008-11-05
ATE509621T1 (de) 2011-06-15
CL2007002387A1 (es) 2008-01-18
AR062393A1 (es) 2008-11-05
ES2495965T3 (es) 2014-09-17
US9060966B2 (en) 2015-06-23
ATE510536T1 (de) 2011-06-15
CL2007002385A1 (es) 2008-01-18
AR062399A1 (es) 2008-11-05
WO2008020034A1 (en) 2008-02-21
PT2056805E (pt) 2011-09-02

Similar Documents

Publication Publication Date Title
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
ECSP109900A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
HRP20090017T3 (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CR20120084A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
ES2531516T3 (es) Uso de escina
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas

Legal Events

Date Code Title Description
FB Suspension of granting procedure